A major challenge of cancer immunotherapy is the persistence and outgrowth of subpopulations that lose expression of the target antigen. IL-15 is a potent cytokine that can promote organ-specific autoimmunity when up-regulated on tissue cells. Here we report that T cells eradicated 2-wk-old solid tumors that expressed IL-15, eliminating antigen-negative cells. In contrast, control tumors that lacked IL-15 expression consistently relapsed. Interestingly, even tumors lacking expression of cognate antigen were rejected when expressing IL-15, indicating that rejection after adoptive T-cell transfer was independent of cognate antigen expression. Nevertheless, the T-cell receptor of the transferred T cells influenced the outcome, consistent with the notion that T-cell receptor activation and effector status determine whether IL-15 can confer lymphokine killer activity-like properties to T cells. The effect was limited to the microenvironment of tumors expressing IL-15; there were no noticeable effects on contralateral tumors lacking IL-15. Taken together, these results indicate that expression of IL-15 in the tumor microenvironment may prevent the escape of antigen loss variants and subsequent tumor recurrence by enabling T cells to eliminate cancer cells lacking cognate antigen expression in a locally restricted manner.
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T he relapse rate among cancer patients remains high, despite initial success with various treatments, owing to outgrowth of resistant cancer variants. Adoptively transferred cytotoxic T cells have the advantage of potentially achieving sterilizing immunity, killing cancerous cells much like infected cells. In support of this strategy, CD8
+ T-cell infiltration into tumors is associated with a better prognosis (1) (2) (3) (4) . Furthermore, in mouse models, tumorspecific CD8 + T cells prevent growth and can be used to treat wellestablished tumors in adoptive therapy (5) . However, cancer may relapse through the escape of antigen loss variants that are insensitive to antigen-specific CD8
+ T cells (6) (7) (8) , impeding efforts of adoptive T-cell therapy.
IL-15 has multiple functions in the immune system and signals through a heterodimer composed of IL-2 receptor beta (IL-2Rβ) and the common gamma chain (γC) (9, 10) . The unique highaffinity receptor alpha chain (IL-15Rα) presents IL-15 in trans to IL-2Rβ/γC on neighboring cells. Importantly, IL-15 is commonly found in the inflamed tissues of patients with autoimmune disorders and celiac disease, where it may promote tissue damage (11, 12) , either by serving as a costimulatory molecule for the T-cell receptor (TCR) (13) (14) (15) or by endowing T cells through the licensing of natural killer group 2D receptor (NKG2D) to exert lymphokine-activated killer (LAK) activity (13, (15) (16) (17) . LAK activity by cytotoxic T cells, previously dismissed as an in vitro artifact, has been correlated with IL-15 expression by intestinal cells in individuals with celiac disease (13, 15, 18, 19) . However, previous studies in humans were correlative in nature and could not determine whether killing of epithelial cells in a noncognate manner involves low-affinity TCR recognition of self or microbial antigens.
Antitumor activity of IL-15 in vivo has been reported in two types of regimens. In the first type, IL-15 was added to cultures during activation of tumor-specific T cells in vitro before adoptive transfer (20) (21) (22) ; in the second, IL-15 was given systemically (23) (24) (25) . These reports examined the effects of IL-15 in cancer models, although treatments either were given before tumors had been established or produced only partial responses. Other studies examining the effects of IL-15 expression by cancer cells have suggested that IL-15 can prevent tumor outgrowth and/or metastasis (26) , and our laboratories have recently shown the eradication of established IL-15-expressing tumors by densely granulated natural killer (NK) cells (27) .
Based on accumulating evidence that IL-15 requires cell contact to function (27) (28) (29) and that it promotes organ-specific autoimmunity when expressed by tissue cells (30), we postulated that if cancerous cells expressed IL-15, then they could endow cytotoxic T cells with the ability to reject large established tumors and even prevent relapse. To test this idea, we adoptively transferred CD8
+ T cells into mice bearing well-established tumors expressing IL-15 and evaluated tumor regression and regrowth. Our results show that IL-15 elicits a powerful response against established solid tumors and may be a more powerful costimulatory molecule for the TCR than previously thought, in that it could even endow the TCR with the ability to mediate cytolysis of tumors lacking expression of cognate antigens.
Results
We previously reported that cancer cells expressing low antigen levels relapse after treatment with specific CD8 + T cells, whereas tumors expressing high levels of antigens are completely rejected (31) . We wanted to determine whether IL-15 in the tumor microenvironment would endow antigen-specific cytotoxic T cells with the ability to prevent tumor escape despite low levels of antigen expression in the same tumor model. To this effect, we transduced the fibrosarcoma mesenchymal cell line MC57 to express low levels of a fusion protein of an SIYRYYGL (SIY) peptide trimer and EGFP with either IL-15 (32) in an enhanced cyan fluorescent protein (ECFP) vector (M-SIY-IL15) or the empty vector (M-SIY) ( Fig. 1A and Table S1 ). M-SIY and M-SIY-IL15 have similar EGFP and ECFP fluorescence (Fig. 1B) , have been shown to secrete IL-15 (27) , and exhibit comparable growth before treatment ( Fig. 1C and Fig. S1 ).
We opted to use Rag , were transferred to treat tumor-bearing animals. M-SIY tumors expressing only antigen shrank initially, but eventually escaped (Fig. 1C) . Cancer cells from escaping tumors were readapted to culture, and analysis revealed that although they expressed EGFP before inoculation (Fig. 1B) , they no longer did so after tumor outgrowth, and thus the relapsing tumor was composed of antigen-negative cells (Fig. 1D) . ECFP expression was maintained, confirming no selection for loss of the empty vector. In contrast, tumors expressing SIY and IL-15 conjointly were completely rejected without relapse (Fig. 1C) . (In this study, we defined relapse as progressive regrowth, after regression, by day 65.) This effect was dependent on treatment, as demonstrated by the fact that M-SIY-IL15 tumors grew progressively when no T cells were transferred. Taken together, these results indicate that IL-15 expression in the tumor microenvironment induced 2C T cells to prevent escape of antigen-negative cells, thereby preventing tumor relapse.
To further characterize how IL-15 functions in preventing tumor relapse, we wanted to know whether the effects of IL-15 were systemic, given the consistent evidence suggesting that IL-15 functions in a cell contact-dependent manner (28, 29) . To investigate this possibility, we first measured the percentage of circulating 2C T cells after transfer into Rag (Table S1 ). After 2 wk, once the tumors were established, we transferred 2C splenocytes and monitored tumor growth. To our surprise, 2C T cells eradicated MC57 tumors in the absence of cognate antigen expression when they expressed IL-15 (in 13 of 14 mice; Fig. 3 and Table 1 ). We excluded the possibility that this effect was linked to expression of non-2C Tcell receptors on 2C T cells by reproducing the effect using 2C/ Rag −/− splenocytes (Fig. 3 ). Anti-CD8 antibody treatment at the time of T-cell transfer protected the tumors from rejection, thereby affirming a requirement for CD8 + T cells in the IL-15-mediated antitumor effect (Fig. 3) . In contrast to the M-IL15 tumors, all M-control tumors lacking IL-15 expression relapsed after various intervals. Taken together, these results suggest that IL-15 expression in the tumor can lead to eradication of large established tumors in the absence of cognate antigen expression. We next wanted to determine how IL-15 mediates its antitumor effects. Having found that in the presence of IL-15, tumors isolated from Rag −/− γC −/− hosts after 2C/Rag −/− T-cell treatment displayed higher levels of IFN-γ in total tissue homogenates (Fig.  S2A) , we wanted to ascertain the role of IFN-γ. We found that neutralization with anti-IFN-γ antibody prevented tumor regression in presence or absence of IL-15 expression by MC57 tumors (Fig. S2B) . Next, knowing that IL-15 up-regulates the expression of cytolytic granules in CD8 + T cells (16), we evaluated the frequency of perforin-positive 2C T cells, and found a significantly higher frequency in M-IL15 tumors compared with M-control tumors (Fig. 4A) . Using perforin-deficient 2C T cells, we found that tumors regressed in absence of perforin, but that IL-15 could no longer prevent tumor relapse in four of six mice (Fig. 4B) , indicating that induction of perforin is critical to the antitumor properties of IL-15.
After finding that IL-15 endows 2C T cells with potent antitumor properties in the absence of cognate antigen expressed by cancer cells, we wanted to examine the role of the TCR in this process. This was prompted by the finding that NKG2D is not required for the IL-15-mediated antitumor effects on MC57 (Fig.  S3) . We had investigated the role of NKG2D, because MC57 tumors expressed the NKG2D ligand RNA export 1 (Rae-1) (33) (Fig. S3A) , and NKG2D was up-regulated on 2C T cells after transfer into tumor-bearing mice (Fig. S3B) . Furthermore, NKG2D has been shown to mediate LAK activity in human CD8 + T cells activated by IL-15 (13, 15, 18) . To further evaluate the role of the TCR, we assessed how IL-15 affected the ability of T cells with a polyconal TCR repertoire to reject and prevent relapse of large established tumors. Interestingly, in contrast to 2C T cells, which were able to shrink tumors independently of IL-15, polyclonal T cells were able to shrink established tumors only in the presence of IL-15 (Fig. S4) . Furthermore, they prevented tumor relapse, similar to 2C T cells (Fig. S4) .
To examine the involvement of the TCR more specifically, we treated tumors with splenocytes from mice transgenic for the OT-1 TCR, specific for an ovalbumin peptide presented by K b . Our first striking finding was that OT-1 T cells, in contrast to 2C T cells, could not shrink established MC57 tumors in the absence of IL-15, suggesting that 2C and OT-1 TCR transgenic T cells have different intrinsic abilities to recognize and/or eliminate MC57 tumors. Importantly, IL-15 did enhance the antitumor properties of OT-1 T cells, as demonstrated by the ability of OT-1 T cells to shrink large established MC57 tumors expressing IL-15 in the absence of cognate antigen (Fig. 5A and Table 1 ). However, OT-1 in contrast to 2C T cells were unable to prevent relapse ( Fig. 5A and Table 1 ). Of note, 2C and OT-1 T cells displayed similar proliferative capacities when transferred into Rag −/− γC −/− hosts (Fig. S5) . Altogether, these observations suggest that T cells vary in their capacities to eradicate tumors in presence of IL-15 due to differences in their TCR, and this despite the lack of requirement for cognate antigen.
To directly test this hypothesis, we transduced OT-1/Rag −/− splenocytes to express the 2C TCR (OT1-2C). Conspicuously, although only 25% of T cells were transduced, we observed a difference in tumor regression caused by OT-1 and OT1-2C T cells. In particular, OT1-2C T cells rejected the M-IL15 tumor with kinetics similar to 2C T cells and decreased the tumor burden as observed with nontransduced OT-1 T cells (Fig. 5B) ; nevertheless, tumor relapse occurred. Thus, it appears that the TCR is likely involved in the rejection process of M-IL15 tumors by 2C Table 1 . (Fig.  S6B) , suggesting that these receptors may be implicated along with the TCR in the tumor rejection process.
Discussion
This study has revealed that IL-15 expression in the tumor environment has a dramatic effect on T-cell-mediated rejection of established tumors. We showed that the presence of IL-15 could prevent the relapse of loss variants after treatment with tumorspecific T cells. Furthermore, we found that IL-15 enhances the antitumor properties of T cells in a noncognate, yet TCR-and perforin-dependent, mechanism. The antitumor effects of IL-15 observed in this study are likely underestimated, given our previous findings that NK cells are empowered to reject established tumors in the presence of IL-15 (27) , and the fact that the experimental systems used here excluded the effect of NK cells. It remains to be deternined whether the combined effect of IL-15 on NK cells and T cells can prevent tumor relapse under suboptimal conditions (e.g., after transfer of OT-1 cells).
Our data suggest that IL-15 promotes regression and even elimination of established solid tumors lacking expression of cognate antigens by endowing CD8 + T cells with potent LAK activity in vivo. Given that the nature of the TCR and MHC class I expression influences the elimination of tumor cells, acquisition of LAK activity by CD8 + T cells likely involves reduction of the TCR activation threshold, leading to recognition of self or tumor peptides that otherwise would be inconsequential. IL-15 could costimulate the TCR directly by activating phosphoinositide 3-kinase or indirectly by promoting the expression and/or activation of costimulatory NK receptors, such as NKG2D (13, 15) . Although we found NKG2D to be dispensable for tumor rejection (Fig.  S3C) , we have not ruled out the possible involvement of NK receptors with stimulatory properties (it is possible that there is a redundancy between activating NK receptors). In fact, tumors lacking MHC class I expression were significantly reduced in size after treatment, and activating NK receptors, including natural killer cell group 2E and 2C (NKG2E/C), and the MHC class I specific C-type lectin NK receptor Ly49D, were up-regulated on CD8
+ T cells transferred into IL-15 tumor-bearing mice (Fig.  S6B) . These activating NK receptors may have overlapping functions with the TCR and/or play a role in reducing the TCR activation threshold. Thus, in contrast to our original thinking, we now argue that acquisition of LAK activity by CD8 + T cells in the presence of IL-15 might involve both the TCR and activating NK receptors. The use of redundant effector mechanisms in the elimination of tumors is now a well-established concept. For instance, it has been shown that the knockdown of effector molecules, such as IFN-γ and TNF-α, in T cells does abrogate full tumor rejection, but does not prevent regression of tumors expressing the cognate antigen (31, 34, 35) .
These results have important implications for the design of IL-15 immunotherapy. They demonstrate that cognate antigens are not required for the antitumor properties of T cells in the presence of IL-15. However, they also indicate that the extent to which IL-15 can exert its antitumor effect, and in particular prevent relapse of large established tumors, will rely on the selection of T cells used for immunotherapy. Here we show that certain T-cell clones (e.g., 2C) may exert stronger antitumor effects than others (e.g., OT-1). Importantly, however, polyclonal T cells with a WT repertoire fully reject IL-15-secreting tumors (i.e., there is no tumor relapse in presence of IL-15), suggesting that the use of polyclonal T cells in combination with IL-15 in cancer therapy may have advantages over the use of clonal T cells, which would need to be evaluated individually for their antitumor effects. Our findings further imply that therapeutic strategies should aim to bring IL-15 to the tumor. We believe that the major effects of IL-15 that we have identified (i.e., its ability to promote regression and even prevent relapse of established tumors) are associated with our decision to have IL-15 expressed by the cancer cells instead of administering it systemically or in T-cell cultures before treatment (20) (21) (22) (23) (24) (25) . Nevertheless, this does have the potential for clinical application through the use of advanced molecular engineering to target tumors. The expression of IL-15Rα on cancer and stromal cells, along with local IL-15 levels, are important for the activation of both T and NK cells for effective tumor eradication. Not all cancer cells express Rα, and soluble IL-15:IL-15Rα conjugates have been shown to be functional in vivo (36) . Coupling these conjugates to tumor-specific receptors, such as antibodies, single-chain variable fragments (scFv), and single-chain soluble TCRs, should enable the effective delivery of these conjugates to tumors. The use of receptor-redirected T cells as delivery vehicles has been studied as well (37) . We predict that once a proper method of administration is established, IL-15 will advance efforts in preventing relapse caused by the persistence of cells lacking cognate antigen expression, which continues to hinder cancer treatment. deficient cancer cell line 9604 has been described previously (27) . The IL-15 cDNA sequence containing the IL-2 signal peptide (IL-2SP) was kindly provided by M. Caligiuri (Ohio State University, Columbus, OH) (32) . Primers (5′) 5′ GGGGTCTCGCATGTACAGCAT GCAGCTCG 3′ and (3′) 5′ GGCTCGAGC-TATTTGTCATCGTCGTCCTTG 3′ (Integrated DNA Technologies) were used for cloning into the pMFG-IRES-ECFP plasmid (IL-15-ECFP). The plasmid pMFG-IL15Rα has been described previously (27) . pLXIN-K b was generated by clon- 9604-IL15. The 9604-IL15-K b cell line was also transduced and sorted to express K b ; both cell lines were also transduced to express IL15Rα. Isolation of Cancer and Stromal Cells. For the analysis of cancer and stromal cells ex vivo, tumors were surgically excised and placed in PBS, minced into 1-mm 3 pieces, and incubated for 30 min in 2 mg/mL collagenase D and 100 U/mL DNase I (both Roche Diagnostics). Tumor fragments were pipetted up and down for 2 min after the addition of prewarmed trypsin (0.025% final concentration; Gibco). Suspensions were spun down, washed, and filtered through a 70-μm nylon mesh, resulting in a single-cell suspension, which was used for flow cytometry analysis (for perforin and granzyme) or readaptation to culture in vitro. Alternatively, needle biopsy specimens from escaping tumors were collected and cultured before analysis.
FACS Analysis. Samples were Fc-blocked and stained with antibodies at 4°C. Peripheral blood was first treated with Tris/NH 4 Cl. FACS data were collected with a FACScalibur or LSRII flow cytometer (BD Biosciences) and analyzed using FloJo software (Tree Star).
IFN-γ ELISA. Tumors were harvested, weighed, and immediately frozen at −80°C. Samples were later thawed in 1 mL PBS and subjected to homogenization with a glass tissue grinder, then assayed with an IFN-γ ELISA Kit (eBioscience).
Statistics. Tumor regression and relapse rates were compared using Fisher's exact test for two-tailed P values. Blood samples and average tumor sizes were compared using an unpaired Student t test.
